1. S. El Hallani, F. Ducray, A. Idbaih, Y. Marie, B. Boisselier, C. Colin, F. Laigle-Donadey, M. Rodero, O. Chinot, J. Thillet, K. Hoang-Xuan, J. Y. Delattre, and M. Sanson. TP53 codon 72 polymorphism is associated with age at onset of glioblastoma. Neurology, 72(4):332-6, 2009. Note: Comparative StudyJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Age Factors, Age of Onset, Aged, Aged, 80 and over, Codon/blood/*genetics, Female, Follow-Up Studies, Gene Frequency/genetics, Genetic Variation/genetics, Glioblastoma/blood/epidemiology/*genetics, Humans, Male, Middle Aged, Mutation/genetics, Polymorphism, Single Nucleotide/*genetics, Tumor Suppressor Protein p53/blood/*genetics, Young Adult.



2. F. Keime-Guibert, O. Chinot, L. Taillandier, S. Cartalat-Carel, M. Frenay, G. Kantor, J. S. Guillamo, E. Jadaud, P. Colin, P. Y. Bondiau, P. Menei, H. Loiseau, V. Bernier, J. Honnorat, M. Barrie, K. Mokhtari, J. J. Mazeron, A. Bissery, and J. Y. Delattre. Radiotherapy for glioblastoma in the elderly. N Engl J Med, 356(15):1527-35, 2007. Note: Association of French-Speaking Neuro-OncologistsComparative StudyJournal ArticleMulticenter StudyRandomized Controlled TrialResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Aged, Aged, 80 and over, Astrocytoma/mortality/radiotherapy/therapy, Brain Neoplasms/mortality/*radiotherapy/therapy, Cognition/radiation effects, Female, Glioblastoma/mortality/*radiotherapy/therapy, Humans, Male, Proportional Hazards Models, Quality of Life, Radiotherapy Dosage, Survival Analysis.



3. D. Galanaud, F. Nicoli, O. Chinot, S. Confort-Gouny, D. Figarella-Branger, P. Roche, S. Fuentes, Y. Le Fur, J. P. Ranjeva, and P. J. Cozzone. Noninvasive diagnostic assessment of brain tumors using combined in vivo MR imaging and spectroscopy. Magn Reson Med, 55(6):1236-45, 2006. Note: Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited Statesofficial journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine. [WWW] Keyword(s): Artificial Intelligence, Brain Neoplasms/*diagnosis, Contrast Media, Diagnosis, Computer-Assisted/*methods, Discriminant Analysis, Gadolinium DTPA/*diagnostic use, Humans, Magnetic Resonance Imaging/*methods, Magnetic Resonance Spectroscopy/*methods, Reproducibility of Results, Sensitivity and Specificity, Systems Integration.



4. M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, H. Gervais, F. Laigle, A. Carpentier, K. Mokhtari, L. Taillandier, O. Chinot, H. Duffau, J. Honnorat, K. Hoang-Xuan, and J. Y. Delattre. Initial chemotherapy in gliomatosis cerebri. Neurology, 63(2):270-5, 2004. Note: ANOCEF groupClinical TrialComparative StudyControlled Clinical TrialJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Alkylating/adverse effects/*therapeutic use, Antineoplastic Combined Chemotherapy Protocols/administration &, dosage/adverse effects/*therapeutic use, Astrocytoma/drug therapy/radiotherapy, Brain Neoplasms/*drug therapy/pathology/radiotherapy, Combined Modality Therapy, Cranial Irradiation, Dacarbazine/adverse effects/*analogs & derivatives/*therapeutic use, Disease Progression, Disease-Free Survival, Drug Administration Schedule, Female, Hematologic Diseases/chemically induced, Humans, Karnofsky Performance Status, Lomustine/administration & dosage/adverse effects, Magnetic Resonance Imaging, Male, Middle Aged, Neoplasms, Neuroepithelial/*drug therapy/pathology/radiotherapy, Oligodendroglioma/drug therapy/radiotherapy, Procarbazine/administration & dosage/adverse effects, Survival Analysis, Treatment Outcome, Vincristine/administration & dosage/adverse effects.



5. D. Galanaud, O. Chinot, F. Nicoli, S. Confort-Gouny, Y. Le Fur, M. Barrie-Attarian, J. P. Ranjeva, S. Fuentes, P. Viout, D. Figarella-Branger, and P. J. Cozzone. Use of proton magnetic resonance spectroscopy of the brain to differentiate gliomatosis cerebri from low-grade glioma. J Neurosurg, 98(2):269-76, 2003. Note: Evaluation StudiesJournal ArticleResearch Support, Non-U.S. Gov'tUnited States. [WWW] Keyword(s): Adolescent, Adult, Aged, Brain/*metabolism/*pathology/physiopathology, Brain Neoplasms/*metabolism/*pathology/physiopathology, Diagnosis, Differential, Female, Glioma/*metabolism/*pathology/physiopathology, Humans, *Magnetic Resonance Imaging, *Magnetic Resonance Spectroscopy, Male, Middle Aged, Neoplasms, Neuroepithelial/*metabolism/*pathology/physiopathology, Prospective Studies, Sensitivity and Specificity, Time Factors.



6. K. Hoang-Xuan, L. Taillandier, O. Chinot, P. Soubeyran, U. Bogdhan, J. Hildebrand, M. Frenay, N. De Beule, J. Y. Delattre, and B. Baron. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study (26952) of the European Organization for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol, 21(14):2726-31, 2003. Note: European Organization for Research and Treatment of Cancer Brain Tumor GroupClinical TrialClinical Trial, Phase IIComparative StudyJournal ArticleMulticenter StudyUnited Statesofficial journal of the American Society of Clinical Oncology. [WWW] Keyword(s): Age Factors, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols/*administration &, dosage/adverse effects, Belgium, Biopsy, Needle, Central Nervous System Neoplasms/*drug therapy/mortality/*pathology, Cytarabine/administration & dosage/adverse effects, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, Humans, Infusions, Intravenous, Injections, Spinal, Lomustine/administration & dosage/adverse effects, Lymphoma/*drug therapy/mortality/*pathology, Male, Methotrexate/administration & dosage/adverse effects, Methylprednisolone/administration & dosage/adverse effects, Middle Aged, Multivariate Analysis, Neoplasm Staging, Probability, Procarbazine/administration & dosage/adverse effects, Research, Risk Assessment, Survival Analysis, Treatment Outcome.

This material is presented to ensure timely dissemination of scholarly and technical work. Copyright and all rights therein are retained by authors or by other copyright holders. All person copying this information are expected to adhere to the terms and constraints invoked by each author's copyright. In most cases, these works may not be reposted without the explicit permission of the copyright holder.

Les documents contenus dans ces répertoires sont rendus disponibles par les auteurs qui y ont contribué en vue d'assurer la diffusion à temps de travaux savants et techniques sur une base non-commerciale. Les droits de copie et autres droits sont gardés par les auteurs et par les détenteurs du copyright, en dépit du fait qu'ils présentent ici leurs travaux sous forme électronique. Les personnes copiant ces informations doivent adhérer aux termes et contraintes couverts par le copyright de chaque auteur. Ces travaux ne peuvent pas être rendus disponibles ailleurs sans la permission explicite du détenteur du copyright.

This document was translated from BibT_EX by bibtex2html